Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 4/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.42 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | PI4KA | P42356 | 2/20 | 0.38 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.38 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.38 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21878182 | 0.88 | FBP1 (0.41) | FBP1ADORA2AADORA1KMT2A | |
| SCHEMBL21877957 | 0.81 | FBP1 (0.42) | FBP1ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL987114 | 0.77 | ADORA2A (0.62) | FBP1ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL21878072 | 0.72 | ALDH1A1 (0.40) | FBP1ADORA2AKMT2A | |
| SCHEMBL982883 | 0.71 | HSPA5 (0.40) | FBP1ADORA2AADORA1HSP90AA1HSP90AB1 | |
| SCHEMBL30366879 | 0.71 | VCP (0.37) | KMT2AMAPK1 | |
| SCHEMBL2751787 | 0.69 | TLR8 (0.54) | KMT2A | |
| SCHEMBL5376477 | 0.69 | FBP1 (0.76) | FBP1ADORA2AADORA1HSP90AA1HSP90AB1 | |
| SCHEMBL21877980 | 0.68 | ADORA3 (0.43) | FBP1ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL5358021 | 0.67 | ADORA2A (0.69) | FBP1ADORA2AADORA1HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3873484-B1 | NOVEL STING AGONISTS | VENENUM BIODESIGN LLC (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-3873484-B1 | NOVEL STING AGONISTS | VENENUM BIODESIGN LLC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20220048936-A1 | NOVEL STING AGONISTS | Venenum Biodesign, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-11161864-B2 | Sting agonists | Venenum Biodesign, LLC (US) | 2021-11-02 | — | — | US | disclosed |
| US-11161864-B2 | Sting agonists | Venenum Biodesign, LLC (US) | 2021-11-02 | — | — | US | disclosed |
| US-20200131209-A1 | NOVEL STING AGONISTS | Venenum Biodesign, LLC | 2020-04-30 | — | — | US | disclosed |
| US-20200131209-A1 | NOVEL STING AGONISTS | Venenum Biodesign, LLC | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131209-A1 | NOVEL STING AGONISTS | STING1, CGAS, TBK1 | FBP1 3836/4885ADORA2A 283/4885ADORA1 71/4885 |
| US-11161864-B2 | Sting agonists | STING1, IRF3, CGAS | FBP1 3653/4885ADORA2A 342/4885ADORA1 77/4885 |
| US-20220048936-A1 | NOVEL STING AGONISTS | STING1, IRF3, CGAS | FBP1 3622/4885ADORA2A 267/4885ADORA1 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.